TYME Tyme Technologies, Inc. Stock Quote

TYME [NASD]

Index	-	P/E	-	EPS (ttm)	-0.22	Insider Own	28.60%	Shs Outstand	130.17M	Perf Week	-0.66%
Market Cap	260.76M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	-4.04%	Shs Float	107.40M	Perf Month	28.21%
Income	-27.50M	PEG	-	EPS next Q	-	Inst Own	11.80%	Short Float	4.23%	Perf Quarter	-26.47%
Sales	-	P/S	-	EPS this Y	40.40%	Inst Trans	31.92%	Short Ratio	1.57	Perf Half Y	36.36%
Book/sh	0.07	P/B	21.43	EPS next Y	20.00%	ROA	-120.50%	Target Price	-	Perf Year	16.73%
Cash/sh	0.08	P/C	19.32	EPS next 5Y	-	ROE	-188.10%	52W Range	0.85 - 4.99	Perf YTD	22.95%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-69.94%	Beta	1.02
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	-	Gross Margin	-	52W Low	76.47%	ATR	0.13
Employees	18	Current Ratio	3.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.69	Volatility	9.20% 9.29%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	24.30%	Profit Margin	-	Rel Volume	2.69	Prev Close	1.59
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jun 10 AMC	Payout	-	Avg Volume	2.89M	Price	1.50
Recom	2.00	SMA20	4.20%	SMA50	1.24%	SMA200	3.14%	Volume	7,785,404	Change	-5.66%

Jun-10-21 04:17PM	Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results Business Wire
May-26-21 08:05AM	TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET Business Wire +6.77%
May-13-21 09:05AM	TYME Appoints Frank L. Porfido as Chief Financial Officer Business Wire
May-10-21 09:05AM	TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting Business Wire -8.14%
Apr-01-21 08:00AM	TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer Business Wire +5.06%
Mar-15-21 10:38AM	Is Tyme Technologies, Inc.'s (NASDAQ:TYME) Shareholder Ownership Skewed Towards Insiders? Simply Wall St. +11.27%
Feb-09-21 12:00PM	Why Tyme Technologies Stock Is Taking Off Today Motley Fool +23.95%
Feb-08-21 12:46PM	TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock Business Wire +10.50%
Feb-04-21 02:00PM	Why Tyme Stock Got Demolished Today Motley Fool -35.98%
08:00AM	TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results Business Wire
07:21AM	The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga
07:15AM	Why viral stocks are here to stay Yahoo Finance
01:22AM	TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Business Wire
Feb-03-21 12:30PM	Why Tyme Technologies Stock Is Crushing It Today Motley Fool +93.96%
08:00AM	TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections Business Wire
Jan-08-21 04:02PM	SemiLEDs Reports First Quarter Fiscal Year 2021 Financial Results Business Wire
Jan-06-21 04:01PM	SemiLEDs to Announce Fiscal First Quarter 2021 Financial Results on Friday, January 8, 2021 Business Wire +5.80%
Dec-23-20 11:33AM	Insider Sells Tyme Technologies Shares Benzinga
Dec-15-20 03:47AM	We're Keeping An Eye On Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate Simply Wall St.
Dec-09-20 08:00AM	TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium Business Wire
Nov-30-20 08:00AM	TYME Builds Leadership Team with Announcement of New CEO Business Wire
Nov-27-20 11:00AM	Is Tyme Technologies, Inc. (TYME) Going to Burn These Hedge Funds? Insider Monkey
Nov-12-20 08:00AM	TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results Business Wire
Oct-13-20 08:00AM	Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020 Business Wire
Sep-16-20 02:05PM	Is Tyme Technologies, Inc.'s (NASDAQ:TYME) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Sep-15-20 08:00AM	TYMEs Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New Drugs Business Wire
Sep-14-20 08:00AM	Tyme Technologies to Present at BioNJs 10th Annual BioPartnering Conference on October 6, 2020 Business Wire +6.26%
Sep-09-20 08:00AM	Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020 Business Wire
Sep-02-20 08:00AM	Tyme Technologies to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020 Business Wire +5.56%
Aug-26-20 08:00AM	TYMEs Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19 Business Wire
Aug-21-20 08:00AM	Tyme Technologies to Present at the 2020 CHINABIO® Partnering Forum Business Wire
Aug-19-20 08:00AM	TYME Announces Appointment of John Rothman, Ph.D. to Executive Vice President, Product Development Business Wire
Aug-18-20 11:43AM	Insider Sells Tyme Technologies's Shares Benzinga
Aug-11-20 08:00AM	TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II Study Business Wire
Aug-03-20 11:05AM	Why Tyme Technologies's Stock Is Trading Higher Today Benzinga +13.45%
08:00AM	TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer Business Wire
Jul-21-20 08:00AM	Tyme Technologies to Present at Canaccord 40th Annual Growth Conference on August 13, 2020 Business Wire
Jul-14-20 10:38AM	Insider Sells Tyme Technologies' Stock Benzinga +5.88%
Jul-13-20 05:00PM	TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results Business Wire
Jul-10-20 08:00AM	Tyme Technologies Announces Virtual 2020 Annual Meeting of Stockholders Business Wire
Jul-07-20 10:42AM	Insider Sells Tyme Technologies Shares Benzinga -5.26%
Jun-23-20 08:00AM	TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020 Business Wire -6.54%
Jun-22-20 08:00AM	TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 Business Wire +12.92%
Jun-04-20 05:10PM	Hedge Funds Are Nibbling On Tyme Technologies, Inc. (TYME) Insider Monkey
May-28-20 08:00AM	TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting Business Wire
May-27-20 08:00AM	Tyme Technologies to Present at BIO Digital from June 8-12, 2020 Business Wire
May-20-20 04:05PM	TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Business Wire
03:00PM	Tyme Technologies, Inc. to Host Earnings Call ACCESSWIRE
May-19-20 08:00AM	Tyme Technologies to Present at Jefferies Virtual Healthcare Conference on June 3, 2020 Business Wire
May-15-20 08:00AM	TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020 Business Wire +7.14%
May-12-20 08:00AM	Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020 Business Wire
May-06-20 10:41AM	How Tyme Technologies, Inc. (NASDAQ:TYME) Can Impact Your Portfolio Volatility Simply Wall St.
Apr-06-20 08:30AM	Tyme Technologies to Present at the 2020 Cross-Border Healthcare Webinar Series Business Wire +10.18%
Feb-05-20 08:00AM	TYME Announces Third Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Jan-27-20 08:00AM	Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care GlobeNewswire
Jan-16-20 08:00AM	TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas GlobeNewswire +12.07%
Jan-09-20 08:40AM	Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study Zacks
Jan-08-20 10:18AM	Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks
08:00AM	TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire
Jan-07-20 09:25AM	Tyme stock rises on Eage collaboration for cancer drug MarketWatch +13.64%
07:20AM	Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer Business Wire
Dec-30-19 11:17AM	Analysts: These 3 Strong Buy Penny Stocks Could Soar in 2020 TipRanks +13.33%
Dec-23-19 02:55PM	Hedge Funds Have Never Been More Bullish On Tyme Technologies, Inc. (TYME) Insider Monkey
Dec-12-19 02:14PM	Wall Street Suggests These Falling Knives GuruFocus.com
Dec-04-19 08:00AM	Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York GlobeNewswire
Nov-25-19 08:00AM	TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer GlobeNewswire
Nov-21-19 08:00AM	Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019 GlobeNewswire +15.24%
Nov-07-19 08:00AM	Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019 GlobeNewswire
Nov-04-19 04:05PM	TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Oct-17-19 04:05PM	TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results GlobeNewswire
11:24AM	Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks
Oct-03-19 01:36PM	How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table? Simply Wall St.
Oct-01-19 08:00AM	TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer GlobeNewswire +6.30%
Sep-30-19 08:00AM	TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer GlobeNewswire -20.13%
Sep-26-19 11:16AM	Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks -6.56%
Sep-25-19 08:00AM	TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer GlobeNewswire
Sep-17-19 08:00AM	Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019 GlobeNewswire
Sep-09-19 09:26AM	Will Tyme Technologies Continue to Surge Higher? Zacks +8.80%
08:00AM	TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019 GlobeNewswire
Sep-04-19 08:00AM	Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019 GlobeNewswire
Aug-12-19 08:00AM	TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019 GlobeNewswire
Aug-09-19 08:00AM	Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019 GlobeNewswire
Aug-08-19 08:00AM	TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Aug-07-19 08:00AM	TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer GlobeNewswire
Aug-01-19 08:00AM	Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019 GlobeNewswire
Jul-29-19 08:00AM	TYME Technologies Announces New Collaboration with NYU Langone to Advance TYMEs Cancer Metabolism-Based Therapy, SM-88 GlobeNewswire
Jul-08-19 08:00AM	REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer GlobeNewswire
Jul-05-19 12:41PM	Tyme Technologies News: Why TYME Stock Is Rocketing InvestorPlace +18.85%
09:46AM	Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study MarketWatch
08:00AM	TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer GlobeNewswire
Jun-27-19 03:48PM	Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years? Simply Wall St. +9.90%
Jun-23-19 11:35AM	Weekly CFO Buys Highlight GuruFocus.com
Jun-07-19 08:00AM	TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019 GlobeNewswire
May-29-19 07:30AM	TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results GlobeNewswire -9.23%
May-28-19 08:31AM	The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset Simply Wall St. -5.80%
08:00AM	Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019 GlobeNewswire
May-24-19 08:00AM	Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019 GlobeNewswire
May-23-19 08:00AM	TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas GlobeNewswire
May-20-19 08:00AM	TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers GlobeNewswire
May-09-19 08:00AM	Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th GlobeNewswire +9.68%

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoffman Steve	Chief Science Officer	Jun 09	Sale	1.58	41,250	65,175	24,075,248	Jun 10 06:00 PM
Hoffman Steve	Chief Science Officer	Jun 08	Sale	1.57	41,250	64,762	24,116,498	Jun 10 06:00 PM
Demurjian Michael	10% Owner	Jun 07	Sale	1.61	20,000	32,210	24,538,546	Jun 08 06:16 PM
Demurjian Michael	10% Owner	Jun 01	Sale	1.58	20,000	31,600	24,558,546	Jun 02 05:57 PM
Hoffman Steve	Chief Science Officer	May 27	Sale	1.47	41,250	60,638	24,157,748	May 28 05:12 PM
Hoffman Steve	Chief Science Officer	May 26	Sale	1.38	41,250	56,925	24,198,998	May 28 05:12 PM
Demurjian Michael	10% Owner	May 24	Sale	1.35	20,000	26,902	24,578,546	May 24 04:41 PM
Demurjian Michael	10% Owner	May 17	Sale	1.31	20,000	26,108	24,598,546	May 18 05:32 PM
Hoffman Steve	Chief Science Officer	May 12	Sale	1.20	41,250	49,500	24,240,248	May 13 05:18 PM
Hoffman Steve	Chief Science Officer	May 11	Sale	1.20	41,250	49,500	24,281,498	May 13 05:18 PM
Demurjian Michael	10% Owner	May 11	Sale	1.23	20,000	24,600	24,618,546	May 12 08:48 AM
Demurjian Michael	10% Owner	May 03	Sale	1.50	20,000	30,090	24,638,546	May 04 04:10 PM
Hoffman Steve	Chief Science Officer	Apr 28	Sale	1.57	41,750	65,548	24,322,748	Apr 29 06:50 PM
Hoffman Steve	Chief Science Officer	Apr 27	Sale	1.56	41,750	65,130	24,364,498	Apr 29 06:50 PM
Demurjian Michael	10% Owner	Apr 26	Sale	1.54	20,000	30,824	24,658,546	Apr 28 08:39 AM
Demurjian Michael	10% Owner	Apr 19	Sale	1.45	20,000	29,000	24,678,546	Apr 20 08:21 AM
Hoffman Steve	Chief Science Officer	Apr 14	Sale	1.56	41,750	65,130	24,406,248	Apr 15 04:29 PM
Hoffman Steve	Chief Science Officer	Apr 13	Sale	1.51	41,750	63,042	24,447,998	Apr 15 04:29 PM
Demurjian Michael	10% Owner	Apr 12	Sale	1.57	20,000	31,400	24,698,546	Apr 13 06:02 PM
Van Tornout Jan M	Acting Chief Medical Officer	Apr 07	Buy	1.70	247	420	1,809	Apr 14 09:39 PM
Van Tornout Jan M	Acting Chief Medical Officer	Apr 06	Buy	1.69	245	414	1,562	Apr 14 09:39 PM
Van Tornout Jan M	Acting Chief Medical Officer	Apr 05	Buy	1.85	1,317	2,436	1,317	Apr 14 09:39 PM
Demurjian Michael	10% Owner	Apr 05	Sale	1.78	20,000	35,600	24,718,546	Apr 07 08:31 AM
Demurjian Michael	10% Owner	Mar 29	Sale	1.73	20,000	34,600	24,738,546	Mar 29 04:39 PM
Hoffman Steve	Chief Science Officer	Mar 26	Sale	1.79	41,750	74,732	24,489,748	Mar 29 04:16 PM
Hoffman Steve	Chief Science Officer	Mar 25	Sale	1.79	41,750	74,732	24,531,498	Mar 29 04:16 PM
Demurjian Michael	10% Owner	Mar 22	Sale	2.07	20,000	41,346	24,758,546	Mar 23 09:14 AM
Demurjian Michael	10% Owner	Mar 16	Sale	2.21	20,000	44,282	24,778,546	Mar 18 04:44 PM
Hoffman Steve	Chief Science Officer	Mar 10	Sale	1.98	41,750	82,665	24,573,248	Mar 11 08:40 PM
Hoffman Steve	Chief Science Officer	Mar 09	Sale	1.92	41,750	80,160	24,614,998	Mar 11 08:40 PM
Demurjian Michael	10% Owner	Mar 08	Sale	1.85	20,000	37,000	24,798,546	Mar 08 05:24 PM
Demurjian Michael	10% Owner	Mar 01	Sale	2.10	20,000	42,018	24,818,546	Mar 01 04:12 PM
Hoffman Steve	Chief Science Officer	Feb 25	Sale	2.13	41,750	88,928	24,656,748	Feb 26 04:06 PM
Hoffman Steve	Chief Science Officer	Feb 24	Sale	2.22	41,750	92,685	24,698,498	Feb 26 04:06 PM
Demurjian Michael	10% Owner	Feb 22	Sale	2.43	20,000	48,614	24,838,546	Feb 23 04:25 PM
Demurjian Michael	10% Owner	Feb 16	Sale	2.77	20,000	55,376	24,858,546	Feb 17 05:15 PM
Hoffman Steve	Chief Science Officer	Feb 11	Sale	2.88	41,750	120,240	24,740,248	Feb 12 04:10 PM
Hoffman Steve	Chief Science Officer	Feb 10	Sale	3.01	41,750	125,667	24,781,998	Feb 12 04:10 PM
Demurjian Michael	10% Owner	Feb 08	Sale	2.45	20,000	49,000	24,878,546	Feb 09 05:46 PM
Demurjian Michael	10% Owner	Feb 01	Sale	1.69	20,000	33,786	24,898,546	Feb 02 05:47 PM
Demurjian Michael	10% Owner	Jan 25	Sale	2.07	20,000	41,426	24,918,546	Jan 27 04:20 PM
Hoffman Steve	Chief Science Officer	Jan 22	Sale	1.72	45,250	77,830	25,823,748	Jan 25 04:05 PM
Hoffman Steve	Chief Science Officer	Jan 21	Sale	1.89	56,250	106,312	25,868,998	Jan 25 04:05 PM
Demurjian Michael	10% Owner	Jan 19	Sale	1.95	20,000	39,022	24,938,546	Jan 21 04:33 PM
Demurjian Michael	10% Owner	Jan 11	Sale	1.62	20,000	32,426	24,958,546	Jan 12 05:00 PM
Hoffman Steve	Chief Science Officer	Jan 06	Sale	1.41	56,250	79,312	24,925,248	Jan 07 04:05 PM
Hoffman Steve	Chief Science Officer	Jan 05	Sale	1.36	56,250	76,500	24,981,498	Jan 07 04:05 PM
Demurjian Michael	10% Owner	Jan 04	Sale	1.28	20,000	25,544	24,978,546	Jan 05 04:46 PM
Demurjian Michael	10% Owner	Dec 28	Sale	1.12	20,000	22,400	24,998,546	Dec 30 09:16 AM
Demurjian Michael	10% Owner	Dec 21	Sale	1.15	20,000	23,000	25,018,546	Dec 23 09:05 AM
Hoffman Steve	Chief Science Officer	Dec 16	Sale	1.12	56,250	63,000	25,037,748	Dec 17 04:05 PM
Hoffman Steve	Chief Science Officer	Dec 15	Sale	1.15	56,250	64,687	25,093,998	Dec 17 04:05 PM
Demurjian Michael	10% Owner	Dec 14	Sale	1.19	20,000	23,800	25,038,546	Dec 15 05:37 PM
Hoffman Steve	Chief Science Officer	Dec 14	Sale	1.20	315,367	378,440	25,150,248	Dec 15 04:10 PM
Hoffman Steve	Chief Science Officer	Dec 11	Sale	1.27	184,633	234,484	25,465,615	Dec 15 04:10 PM
Demurjian Michael	10% Owner	Dec 07	Sale	1.07	20,000	21,348	25,058,546	Dec 08 04:50 PM
Hoffman Steve	Chief Science Officer	Dec 04	Sale	1.06	56,250	59,625	25,650,248	Dec 07 04:09 PM
Hoffman Steve	Chief Science Officer	Dec 03	Sale	1.09	68,406	74,563	25,706,498	Dec 07 04:09 PM
Demurjian Michael	10% Owner	Nov 30	Sale	1.08	20,000	21,600	25,078,546	Dec 01 04:09 PM
Demurjian Michael	10% Owner	Nov 23	Sale	0.93	20,000	18,626	25,098,546	Nov 24 05:20 PM
Hoffman Steve	Chief Executive Officer	Nov 19	Sale	0.94	37,179	34,948	25,774,904	Nov 20 05:02 PM
Hoffman Steve	Chief Executive Officer	Nov 18	Sale	0.94	59,442	55,875	25,812,083	Nov 20 05:02 PM
Demurjian Michael	10% Owner	Nov 16	Sale	0.93	20,000	18,696	25,118,546	Nov 18 07:05 PM
Demurjian Michael	10% Owner	Nov 09	Sale	0.94	20,000	18,734	25,138,546	Nov 10 04:51 PM
Hoffman Steve	Chief Executive Officer	Nov 04	Sale	0.92	11,320	10,414	25,871,525	Nov 05 04:38 PM
Hoffman Steve	Chief Executive Officer	Nov 03	Sale	0.89	29,561	26,309	25,882,845	Nov 05 04:38 PM
Demurjian Michael	10% Owner	Nov 02	Sale	0.86	20,000	17,222	25,158,546	Nov 03 04:32 PM
Hoffman Steve	Chief Executive Officer	Oct 22	Sale	0.98	17,540	17,189	25,912,406	Oct 23 06:30 PM
Hoffman Steve	Chief Executive Officer	Oct 21	Sale	0.98	20,302	19,896	25,929,946	Oct 23 06:30 PM
Demurjian Michael	10% Owner	Oct 19	Sale	1.03	20,000	20,632	25,178,546	Oct 20 04:06 PM
Demurjian Michael	10% Owner	Oct 16	Sale	1.02	20,000	20,468	25,198,546	Oct 19 04:17 PM
Demurjian Michael	10% Owner	Oct 07	Sale	1.00	20,000	19,908	25,218,546	Oct 07 06:02 PM
Hoffman Steve	Chief Executive Officer	Oct 07	Sale	0.99	31,250	30,938	25,950,248	Oct 08 04:55 PM
Hoffman Steve	Chief Executive Officer	Oct 06	Sale	0.99	31,250	30,938	25,981,498	Oct 08 04:55 PM
Demurjian Michael	10% Owner	Oct 02	Sale	0.97	20,000	19,462	25,238,546	Oct 02 06:23 PM
Hoffman Steve	Chief Executive Officer	Sep 23	Sale	0.94	31,250	29,375	26,012,748	Sep 24 04:07 PM
Hoffman Steve	Chief Executive Officer	Sep 22	Sale	0.96	31,250	30,000	26,043,998	Sep 24 04:07 PM
Demurjian Michael	10% Owner	Sep 21	Sale	0.98	20,000	19,576	25,258,546	Sep 22 06:17 PM
Demurjian Michael	10% Owner	Sep 14	Sale	1.03	20,000	20,554	25,278,546	Sep 15 04:56 PM
Hoffman Steve	Chief Executive Officer	Sep 10	Sale	1.01	41,750	42,168	26,075,248	Sep 11 04:05 PM
Hoffman Steve	Chief Executive Officer	Sep 09	Sale	1.01	41,750	42,168	26,116,998	Sep 11 04:05 PM
Demurjian Michael	10% Owner	Sep 08	Sale	1.02	20,000	20,376	25,298,546	Sep 09 09:00 AM
Demurjian Michael	10% Owner	Sep 02	Sale	1.04	20,000	20,810	25,318,546	Sep 03 06:36 PM
Michels Douglas A	Director	Sep 01	Buy	0.96	50,000	48,000	110,000	Sep 03 04:18 PM
Biehl James	Chief Legal Officer	Sep 01	Buy	0.95	10,000	9,500	65,000	Sep 03 04:19 PM
Hoffman Steve	Chief Executive Officer	Aug 27	Sale	1.13	41,750	47,177	26,158,748	Aug 28 04:15 PM
Hoffman Steve	Chief Executive Officer	Aug 26	Sale	1.25	41,750	52,188	26,200,498	Aug 28 04:15 PM
Demurjian Michael	10% Owner	Aug 24	Sale	1.17	20,000	23,400	25,338,546	Aug 24 06:36 PM
Demurjian Michael	10% Owner	Aug 17	Sale	1.29	20,000	25,742	25,358,546	Aug 18 08:37 AM
Hoffman Steve	Chief Executive Officer	Aug 14	Sale	1.19	41,750	49,682	26,242,248	Aug 14 07:03 PM
Hoffman Steve	Chief Executive Officer	Aug 13	Sale	1.20	61,951	74,341	26,283,998	Aug 14 07:03 PM
Demurjian Michael	10% Owner	Aug 10	Sale	1.30	20,000	26,096	25,378,546	Aug 11 04:19 PM
Demurjian Michael	10% Owner	Aug 03	Sale	1.28	20,000	25,650	25,398,546	Aug 04 05:52 PM
Hoffman Steve	Chief Executive Officer	Jul 29	Sale	1.21	44,500	53,845	26,345,949	Jul 30 06:46 PM
Hoffman Steve	Chief Executive Officer	Jul 28	Sale	1.21	51,000	61,710	26,390,449	Jul 30 06:46 PM
Demurjian Michael	10% Owner	Jul 27	Sale	1.22	20,000	24,430	25,418,546	Jul 28 05:09 PM
Demurjian Michael	10% Owner	Jul 20	Sale	1.24	20,000	24,756	25,438,546	Jul 21 08:00 PM
Hoffman Steve	Chief Executive Officer	Jul 16	Sale	1.25	25,500	31,875	26,441,449	Jul 17 05:25 PM
Hoffman Steve	Chief Executive Officer	Jul 15	Sale	1.27	25,799	32,765	26,466,949	Jul 17 05:25 PM
Demurjian Michael	10% Owner	Jul 13	Sale	1.20	20,000	23,996	25,458,546	Jul 14 09:17 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience